Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

United Therapeutics (UTHR) is the sponsoring company for this trial. BiotechSign currently grades this company C (53/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.